XIENCE V
Device
Abbott Laboratories
Total Payments
$660,010
Transactions
1,072
Doctors
326
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $219,013 | 138 | 26 |
| 2023 | $246,401 | 335 | 81 |
| 2022 | $194,596 | 599 | 260 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $356,461 | 268 | 54.0% |
| Unspecified | $165,980 | 114 | 25.1% |
| Grant | $46,682 | 5 | 7.1% |
| Compensation for serving as faculty or as a speaker for a medical education program | $30,750 | 30 | 4.7% |
| Travel and Lodging | $27,703 | 82 | 4.2% |
| Food and Beverage | $20,384 | 568 | 3.1% |
| Charitable Contribution | $8,500 | 3 | 1.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,500 | 1 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $50.00 | 1 | 0.0% |
Payments by Type
General
$494,030
958 transactions
Research
$165,980
114 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized TriaL in PCI | Abbott Laboratories | $136,735 | 0 |
| XIENCE 28 USA Study | Abbott Laboratories | $28,115 | 0 |
| A Clinical Investigation to Assess the Abbott Next Generation Drug Eluting Stent 48mm Everolimus Eluting Coronary Stent System (EECSS) in Treatment of de Novo Native Coronary Artery Disease (SPIRIT 48) | Abbott Laboratories | $600.00 | 0 |
| XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients. | Abbott Laboratories | $320.00 | 0 |
| XIENCE Skypoint Large Vessel Post Approval Study (SPIRIT XLV PAS) | Abbott Laboratories | $210.00 | 0 |
Top Doctors Receiving Payments for XIENCE V
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New Orleans, LA | $205,859 | 129 |
| , MD | Cardiovascular Disease | New York, NY | $80,566 | 74 |
| , MD | Cardiovascular Disease | Brooklyn, NY | $77,316 | 70 |
| , MD | Cardiovascular Disease | Brooklyn, NY | $23,066 | 22 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Paterson, NJ | $20,250 | 12 |
| , MD | Internal Medicine | Baltimore, MD | $19,618 | 18 |
| , M.D | Cardiovascular Disease | New York, NY | $18,250 | 14 |
| , MD | Student in an Organized Health Care Education/Training Program | Manhasset, NY | $18,182 | 1 |
| , MD | Cardiovascular Disease | New York, NY | $17,750 | 21 |
| , M.D | Cardiovascular Disease | New York, NY | $15,500 | 9 |
| , MD | Student in an Organized Health Care Education/Training Program | Ann Arbor, MI | $13,500 | 1 |
| , M.D | Interventional Cardiology | Kyle, TX | $7,500 | 4 |
| , M.D./MBBS | Cardiovascular Disease | Detroit, MI | $7,500 | 1 |
| , M.D | Cardiovascular Disease | San Juan, PR | $7,000 | 3 |
| , MD | Interventional Cardiology | Ann Arbor, MI | $6,625 | 1 |
| , MD | Interventional Cardiology | West Islip, NY | $6,000 | 4 |
| , MD | Internal Medicine | Dallas, TX | $5,400 | 1 |
| , M.D | Student in an Organized Health Care Education/Training Program | New York, NY | $4,500 | 1 |
| , MD | Internal Medicine | Burbank, CA | $4,000 | 2 |
| , MD | Interventional Cardiology | Cleveland, MS | $4,000 | 4 |
| , MD | Emergency Medical Services | San Antonio, TX | $4,000 | 4 |
| , DO | Interventional Cardiology | Roslyn, NY | $3,719 | 5 |
| , M.D | Internal Medicine | Boston, MA | $3,500 | 2 |
| , MD | Internal Medicine | New Haven, CT | $3,500 | 3 |
| , MD | Interventional Cardiology | Eatontown, NJ | $3,500 | 4 |
Ad
Manufacturing Companies
- Abbott Laboratories $660,010
Product Information
- Type Device
- Total Payments $660,010
- Total Doctors 326
- Transactions 1,072
About XIENCE V
XIENCE V is a device associated with $660,010 in payments to 326 healthcare providers, recorded across 1,072 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2022 to 2024. In 2024, $219,013 was paid across 138 transactions to 26 doctors.
The most common payment nature for XIENCE V is "Consulting Fee" ($356,461, 54.0% of total).
XIENCE V is associated with 5 research studies, including "Optical Coherence Tomography (OCT) Guided Coronary Stent Implantation Compared to Angiography: a Multicenter Randomized TriaL in PCI" ($136,735).